Oxford Biomedica Solutions
Troy Panico is a Senior Research Associate in Drug Delivery Sciences at Arbor Biotechnologies, with a focus on producing high titer AAV vectors to support pre-clinical pipeline programs. Prior experience includes a role as Research Associate II at Oxford Biomedica, where Troy designed shake flask experiments to enhance AAV vector productivity and engineered elements of the RepCap protein expression cassette. Early career work at Homology Medicines involved cloning and characterizing plasmids for AAV production and facilitating construct transitions for process development. Additionally, Troy provided academic tutoring services in multiple subjects while pursuing education, earning a Master of Science in Biotechnology from Johns Hopkins University and a Bachelor of Science in Biology and Chemistry from William & Mary.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.